Detection and quantitation of glutamate carboxypeptidase II in human blood

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F14%3A10283895" target="_blank" >RIV/00216208:11310/14:10283895 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61388963:_____/14:00428605 RIV/00064190:_____/14:#0000812 RIV/00216224:14110/14:00075573 RIV/65269705:_____/14:00061559

Výsledek na webu

<a href="http://dx.doi.org/10.1002/pros.22796" target="_blank" >http://dx.doi.org/10.1002/pros.22796</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/pros.22796" target="_blank" >10.1002/pros.22796</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Detection and quantitation of glutamate carboxypeptidase II in human blood

Popis výsledku v původním jazyce

BACKGROUND Glutamate carboxypeptidase II (GCPII) is a transmembrane enzyme that cleaves N-acetyl-L-aspartyl-L-glutamate (NAAG) in the brain. GCPII is highly expressed in the prostate and prostate cancer and might be associated with prostate cancer progression. Another exopeptidase, plasma glutamate carboxypeptidase (PGCP), was reported to be similar to GCPII and to share its NAAG-hydrolyzing activity. METHODS We performed a radioenzymatic assay with [H-3]NAAG as a substrate to detect and quantify the enzymatic activity of GCPII in plasma. Using a specific antibody raised against native GCPII (2G7), we immunoprecipitated GCPII from human plasma. We also cloned two PGCP constructs, expressed them in insect cells, and tested them for their NAAG-hydrolyzing activity. RESULTS We detected GCPII protein in human plasma and found that its concentration ranges between 1.3 and 17.2 ng/ml in volunteers not diagnosed with prostate cancer. Recombinant PGCP was enzymatically active but exhibited no

Název v anglickém jazyce

Detection and quantitation of glutamate carboxypeptidase II in human blood

Popis výsledku anglicky

BACKGROUND Glutamate carboxypeptidase II (GCPII) is a transmembrane enzyme that cleaves N-acetyl-L-aspartyl-L-glutamate (NAAG) in the brain. GCPII is highly expressed in the prostate and prostate cancer and might be associated with prostate cancer progression. Another exopeptidase, plasma glutamate carboxypeptidase (PGCP), was reported to be similar to GCPII and to share its NAAG-hydrolyzing activity. METHODS We performed a radioenzymatic assay with [H-3]NAAG as a substrate to detect and quantify the enzymatic activity of GCPII in plasma. Using a specific antibody raised against native GCPII (2G7), we immunoprecipitated GCPII from human plasma. We also cloned two PGCP constructs, expressed them in insect cells, and tested them for their NAAG-hydrolyzing activity. RESULTS We detected GCPII protein in human plasma and found that its concentration ranges between 1.3 and 17.2 ng/ml in volunteers not diagnosed with prostate cancer. Recombinant PGCP was enzymatically active but exhibited no

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GAP304%2F12%2F0847" target="_blank" >GAP304/12/0847: Glutamátkarboxypeptidasa II a její role v růstu nádorů</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Prostate

ISSN

0270-4137

e-ISSN

—

Svazek periodika

74

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

768-780

Kód UT WoS článku

000334176000008

EID výsledku v databázi Scopus

—